Tivozanib Versus Sorafenib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma: Results From a Phase III Trial

2013442 citationsJournal Articlebronze Open Access

Authors

Robert J. Motzer · Privolzhsky Research Medical University

Dmitry Nosov · Privolzhsky Research Medical University

Timothy Eisen · Privolzhsky Research Medical University

Igor Bondarenko · Privolzhsky Research Medical University

Vladimir Lesovoy · Privolzhsky Research Medical University

Oleg Lipatov · Privolzhsky Research Medical University

Piotr Tomczak

Abstract

Tivozanib demonstrated improved PFS, but not OS, and a differentiated safety profile, compared with sorafenib, as initial targeted therapy for metastatic RCC.

Topics & Keywords

Renal cell carcinoma treatment Renal and related cancers Renal Diseases and Glomerulopathies

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Journal of Clinical Oncology

Volume 31, Issue 30, pp. 3791-3799

DOI: 10.1200/jco.2012.47.4940

Field-Weighted Citation Impact: 37.11